Psilocybin and Bipolar Disorder: Potential and Risks

Psilocybin & Bipolar Disorder

0 manic episodes

In the first clinical trial to directly test psilocybin in bipolar disorder, 19 bipolar II patients received a single 25mg dose with psychotherapy. None developed mania or psychosis over 12 weeks; most achieved remission from depression.

Aaronson et al., JAMA Psychiatry, 2024

19

bipolar II patients in the first dedicated psilocybin trial

1 in 3

naturalistic users reported new or worsening manic symptoms

541

people surveyed about real-world psilocybin use in bipolar disorder

Aaronson et al., JAMA Psychiatry, 2024

View as image ↗

Psilocybin research in people with bipolar disorder has produced two large data points that look contradictory. In 2024, Aaronson and colleagues published the first clinical trial to directly test psilocybin in people with bipolar disorder. Nineteen patients with bipolar II disorder (a form of the condition involving milder mood highs called hypomania, rather than full mania) received a single 25mg dose of synthetic psilocybin with psychotherapy support. Most met remission criteria for their depression within three weeks. None developed mania or psychosis over 12 weeks of follow-up.^[1]

One year earlier, Morton and colleagues had published very different data. They surveyed 541 people with bipolar disorder who had used psilocybin on their own, without clinical support or screening. About one in three reported new or worsening manic or hypomanic symptoms.^[2]

Same drug. Same general population. Very different outcomes.

Understanding what explains that gap is the most practically useful thing this article can do. This piece is part of a broader look at psilocybin research in depression, where bipolar disorder sits as a specific and clinically understudied subcase.

Two Studies, Two Completely Different Answers: Why the Research Looks Contradictory

The gap between the Aaronson 2024 trial and the Morton 2023 survey is large. It is also explainable.

In the clinical trial, participants were carefully screened before enrollment. They had bipolar II disorder specifically, not bipolar I. They had demonstrated mood stability on their current medications. They worked with trained therapists before, during, and after the psilocybin session. The drug was pharmaceutical-grade synthetic psilocybin at a precisely known dose. Researchers monitored them for 12 weeks.

In the Morton survey, none of those conditions applied.^[2] Participants were anonymous online respondents who had used psilocybin in whatever circumstances they found available, at unknown doses, from sources with unknown purity, with no clinical support before or after use. Some had bipolar I, some bipolar II, and others had various related diagnoses. No one assessed their mood stability before they used psilocybin.

The trial does not tell us psilocybin is safe for bipolar patients. It tells us what happens under highly optimized clinical conditions with a specific, lower-risk subgroup. The survey does not tell us psilocybin is dangerous for everyone with bipolar disorder. It tells us what happens when the general bipolar population uses psilocybin outside any clinical context.

A 2026 comprehensive review by Do and colleagues, published in the Journal of Affective Disorders, synthesized trial data, naturalistic surveys, and case reports from across the field. Their finding: the evidence base shows real efficacy signals for depression alongside real safety concerns.^[3] Both signals are meaningful. Neither cancels the other out. The honest picture requires holding both.

The 2024 JAMA Psychiatry Trial: 19 Patients, One Dose, No Mania at 12 Weeks

Aaronson and colleagues at UCSF recruited adults with bipolar II disorder whose depression had not responded to at least two adequate medication trials. Treatment-resistant depression is the clinical term for depression that has failed two or more standard antidepressant treatments. All 19 participants had already tried multiple medications without getting better.

The trial design was nonrandomized and open-label. There was no placebo group. Both patients and researchers knew what was being given. These are real methodological limitations worth stating plainly. Open-label trials can overestimate benefit because expectations on both sides influence the outcome. Results should be interpreted with that in mind.

Each participant received a single 25mg oral dose of synthetic psilocybin. In clinical psilocybin research, 25mg is at the high end of the therapeutic dose range. Sessions were conducted in a dedicated room with two trained therapists present throughout the entire experience. Participants completed preparatory therapy sessions before the dosing day and integration sessions afterward.

The main outcome was depression severity, measured by the Montgomery-Asberg Depression Rating Scale, known as the MADRS. The MADRS asks patients to rate ten areas: things like sadness, inner tension, sleep quality, appetite, and difficulty concentrating. A total score below 10 indicates remission. It is the standard depression measurement in clinical trials because it tracks how patients actually feel day to day, not just their diagnostic category.

Most participants reached the MADRS remission threshold at the three-week assessment. Most maintained remission at twelve weeks. The finding that attracted the most scientific attention: not one participant developed mania, hypomania, psychosis, or worsening suicidal thinking at any point during the 12-week follow-up period.^[1]

JAMA Psychiatry is one of the most selective psychiatry journals in the world. Publication there does not establish psilocybin as a bipolar treatment. It does mean the data passed rigorous peer review and that the results are strong enough to warrant further study.

In 2025, Meshkat and colleagues published a follow-up cohort study in Psychedelic Medicine, adding clinical data from a separate group of bipolar II patients with treatment-resistant depression who received psilocybin-assisted psychotherapy.^[6] The total number of bipolar patients who have received psilocybin in a clinical research setting remains small. The evidence base exists and is growing.

For a deeper look at the Aaronson trial design, its specific findings, and the Meshkat 2025 follow-up, see Psilocybin for Bipolar Depression: Early Research.

What 541 Real-World Users Reported About Psilocybin and Bipolar Disorder

Morton and colleagues recruited 541 adults with bipolar disorder through online psychedelic community networks and asked them about their psilocybin experiences. This was not an experiment. It was a structured survey of people who had already used psilocybin in their own lives, for their own reasons, under their own conditions.

The results were mixed in the way that honest data often is.

Many participants reported meaningful improvements in depression. For people with bipolar disorder, depressive episodes are often the dominant and most disabling phase. Treatments that specifically address depressive episodes without triggering mania are hard to find. Reports of benefit were not incidental or trivial.

But approximately one in three participants also reported adverse effects that included new or worsening manic or hypomanic symptoms.^[2] That rate held up across the data. One in three is not a small minority. It is a substantial portion of a 541-person sample.

The survey's limitations are the same as any retrospective naturalistic study. Participants were not randomly selected; people who had a particularly notable experience, positive or negative, may have been more likely to report it. Some had more severe baseline illness than others. Some used other substances simultaneously. The psilocybin they used came from uncontrolled sources at unknown doses. There was no psychotherapy support before, during, or after use. No clinical monitoring. These conditions represent the highest-risk scenario for any psychedelic use and likely produce worse outcomes than a controlled clinical setting.

What the survey does establish is this: adverse effects in real-world conditions are not rare edge cases. In the general bipolar population using psilocybin outside a clinical context, serious mood destabilization is a common outcome.

For a detailed look at the mania risk research, including individual case reports and what distinguishes high-risk from lower-risk situations, see Psilocybin and Bipolar Depression: Risk of Mania and Emerging Research.

The Lithium Problem: The Most Common Bipolar Medication Creates a Concrete Interaction Risk

Most discussion about psilocybin and bipolar disorder focuses on mood destabilization risk. There is a more specific pharmacological concern that gets far less attention in public-facing coverage.

Lithium is the most commonly prescribed mood stabilizer for bipolar I disorder. It has decades of evidence behind it for preventing manic episodes and is typically a first-line treatment. Many people with bipolar I are on lithium long-term, sometimes for years or decades.

Nayak and colleagues analyzed online psychedelic experience databases, specifically looking for reports of combined use of classic psychedelics, including psilocybin, with lithium. They found a consistent pattern: people taking lithium who used psychedelics reported seizures at a rate that did not appear in reports of other medication pairings.^[4]

The same analysis examined lamotrigine, another mood-stabilizing medication used in bipolar disorder. Reports of psychedelic use combined with lamotrigine showed no comparable seizure pattern.

The data comes from self-reported online accounts, which puts it at the lower end of the evidence quality scale. But the pattern appeared consistently across many independent reports from different sources. The leading explanation involves psilocybin activating serotonin receptors throughout the brain while lithium simultaneously alters the electrical signaling across brain cell membranes. These two effects, happening at the same time, may reduce the threshold at which a seizure occurs. This has not been confirmed in controlled studies, but the observational signal is not ambiguous.

The practical significance is not subtle. Lithium is the first-line treatment for bipolar I disorder, which is already the higher-risk subtype for psilocybin. A bipolar I patient on lithium is not facing an abstract theoretical concern. They are facing a documented risk that is distinct from the mood destabilization question and that careful therapeutic support cannot fully address.

For a structured look at why this and other factors lead clinical researchers to exclude most bipolar patients from psilocybin trials by default, see Why Bipolar Patients Are Excluded from Psilocybin Trials.

Bipolar I and Bipolar II Are Different Conditions — The Risk Calculation Reflects That

The word "bipolar" describes a spectrum, not a single condition. The two main subtypes differ in ways that shape everything about how researchers approach psilocybin safety in this population.

Bipolar I disorder involves at least one episode of severely elevated or irritable mood bad enough to cause major impairment in daily functioning. These episodes, called manic episodes, last at least a week and often require hospitalization. Some include loss of contact with reality, known as psychotic features.

Bipolar II disorder involves a milder form of elevated mood, called hypomania. A hypomanic episode lasts at least four days and involves elevated or irritable mood that is noticeable and different from baseline. It does not reach the severity of full mania. It does not include psychotic features, and it does not typically require hospitalization. Bipolar II patients often spend far more time in depressive episodes than hypomanic ones, and it is the depression that causes the most functional impairment.

These distinctions matter for psilocybin research in two specific ways.

First, the theoretical risk of triggering a severe mood episode is lower in bipolar II. If psilocybin pushes mood upward in a bipolar patient, a bipolar II patient might reach hypomania. A bipolar I patient might reach full mania, potentially with psychosis. This reasoning is precisely why Aaronson and colleagues enrolled bipolar II patients specifically and not bipolar I patients.

Second, the psychosis risk has a different weight depending on history. Psilocybin produces altered perceptions and patterns of thought that can resemble psychotic symptoms in some respects. For a bipolar I patient who has previously experienced psychotic mania, that overlap creates a safety concern that sits in a different category from mood destabilization.

The Do 2026 comprehensive review noted that virtually all controlled clinical trial data in this area applies to bipolar II patients, and that the evidence base for bipolar I patients using psilocybin in any clinical context is essentially absent.^[3] What exists for bipolar I comes primarily from naturalistic surveys and case reports, which is not the same thing.

The Field Is Shifting From Blanket Exclusion Toward Case-by-Case Risk Assessment

Psilocybin clinical trials have historically excluded all people with any personal or family history of bipolar disorder as a blanket policy. The logic: mania induction risk is real and poorly understood, so caution means keeping this entire population out of trials until more data exists.

That position is being systematically questioned.

In 2024, Downey and colleagues published a paper in Psychedelic Medicine under the title "A Plea for Nuance." Their argument was narrow and specific: having a first-degree relative with bipolar disorder, without any personal history of bipolar episodes, is not sufficient clinical justification for excluding someone from a psilocybin trial.^[5]

As applied in many trials, family-history exclusion criteria worked as a rough proxy. Someone whose parent or sibling had bipolar disorder was excluded, even if they had no personal symptoms, no prior mood instability, and no clinical indicators of elevated risk. Downey and colleagues argued that this is not evidence-based risk stratification. It is precautionary exclusion that has not been grounded in systematic risk data, and it may be blocking participation from people whose actual risk is low.

The paper proposed relative exclusion rather than absolute exclusion: assess the type and severity of the family history, the patient's own mental health record, their current mood stability, their medications, and other specific clinical factors. Make the determination individually rather than categorically.

This is not an argument that bipolar patients can safely use psilocybin outside clinical supervision. It is a narrower argument about how clinical trials draw their eligibility criteria, and whether the current approach is more conservative than the actual evidence warrants.

The Do 2026 comprehensive review took a similar position, calling for continued controlled research in bipolar II patients while being clear that the current evidence base is early-stage and that safety monitoring remains essential.^[3] The Aaronson 2024 and Meshkat 2025 trials are exactly the kind of research that position calls for. Their early results have moved the conversation among researchers from "never" toward "carefully, with bipolar II, under close monitoring."

For readers researching psilocybin safety questions in other genetic risk contexts, Family History of Psychosis and Psilocybin: Risk Assessment covers a related exclusion debate for a different but overlapping risk population.

The bipolar II patients in the Aaronson trial were defined by treatment-resistant depression. For broader context on how psilocybin performs in that specific population, see Psilocybin for Treatment-Resistant Depression: When Nothing Else Works.

The Bottom Line

The research on psilocybin and bipolar disorder is early and genuinely mixed. The 2024 Aaronson trial in JAMA Psychiatry found no mania in 19 screened bipolar II patients over 12 weeks, with most achieving remission from depression. The 2023 Morton survey found one in three naturalistic users reported new or worsening manic symptoms. Lithium, the most common bipolar I medication, creates an additional pharmacological risk when combined with psilocybin. The field is moving toward nuanced case-by-case assessment rather than blanket exclusion, but the evidence base remains thin, and the conditions of the clinical setting appear to matter enormously for outcomes.

Frequently Asked Questions

Can psilocybin treat bipolar disorder?

Psilocybin is not an established treatment for bipolar disorder. A 2024 clinical trial in 19 bipolar II patients with treatment-resistant depression found that most achieved remission by week three and maintained it at week twelve with no mania or psychosis. That was a small, open-label study without a control group. A 2026 comprehensive review by Do and colleagues found efficacy signals in the evidence base but concluded the data is too early for clinical conclusions.

Is psilocybin safe for someone with bipolar disorder?

Safety depends heavily on the conditions. In a supervised clinical trial with screened bipolar II patients and full therapeutic support, the 2024 Aaronson trial found no serious adverse events over 12 weeks. In contrast, the 2023 Morton survey of 541 naturalistic users found approximately 1 in 3 reported new or worsening manic symptoms. People with bipolar I disorder on lithium face an additional concern: Nayak and colleagues documented a pattern of seizures in reports of lithium combined with classic psychedelics including psilocybin.

What are the risks of psilocybin for bipolar patients?

Three categories of risk appear in the research. First, mood destabilization: psilocybin activates serotonin receptors and can trigger manic or hypomanic episodes, documented in both population surveys and individual case reports. Second, drug interaction: lithium, the most common bipolar I medication, has been associated with seizures when combined with psilocybin in multiple documented reports. Third, psychosis risk: this applies most specifically to bipolar I patients with a prior history of psychotic features during manic episodes.

Can psilocybin cause mania in bipolar disorder?

Yes. The 2023 Morton survey of 541 bipolar patients found approximately 1 in 3 reported new or worsening manic or hypomanic symptoms after naturalistic psilocybin use. Multiple case reports in the medical literature document manic episodes following psilocybin use in bipolar patients, including at least one case in a person with bipolar II disorder, which is typically considered the lower-risk subtype. The 2024 Aaronson clinical trial found zero mania in 19 carefully screened bipolar II patients, but those participants received full therapeutic support and close monitoring throughout.

Is there research on psilocybin for bipolar depression?

Yes. The Aaronson 2024 JAMA Psychiatry trial is the first published clinical trial to directly test psilocybin for bipolar II depression. Most of the 19 participants achieved remission at three weeks and maintained it at twelve weeks after a single 25mg dose with psychotherapy. In 2025, Meshkat and colleagues published a follow-up cohort study with additional clinical data from bipolar II patients. A 2026 comprehensive review by Do and colleagues synthesized all available evidence including trial data, case reports, and naturalistic surveys.

Sources & References

1. 1RTHM-00863·Aaronson, Scott T et al. (2024). “Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial..” JAMA psychiatry.Study breakdown →PubMed →↩
2. 2RTHM-00846·Morton, Emma et al. (2023). “Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of 'magic mushroom' consumption..” Journal of psychopharmacology (Oxford.Study breakdown →PubMed →↩
3. 3RTHM-00957·Do, André et al. (2026). “Psilocybin use in bipolar disorder: A comprehensive review..” Journal of affective disorders.Study breakdown →PubMed →↩
4. 4RTHM-01412·Nayak, Sandeep M et al. (2021). “Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports..” Pharmacopsychiatry.Study breakdown →PubMed →↩
5. 5RTHM-00875·Downey, Amanda E et al. (2024). “A Plea for Nuance: Should People with a Family History of Bipolar Disorder Be Excluded from Clinical Trials of Psilocybin Therapy?.” Psychedelic medicine (New Rochelle.Study breakdown →PubMed →↩
6. 6RTHM-00944·Meshkat, Shakila et al. (2025). “Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression in Bipolar II Disorder..” Psychedelic medicine (New Rochelle.Study breakdown →PubMed →↩